Fox Run Management, L.L.C. Clovis Oncology, Inc. Transaction History

Fox Run Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 29, 2020	SELL	$4.82 - $7.72 $95,580 - $153,087	-19,830 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$5.69 - $9.69 $112,832 - $192,152	19,830 New	19,830 $134,000
Q1 2019 Oct 17, 2019	SELL	$17.66 - $30.28 $790,708 - $1.36 Million	-44,774 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$11.63 - $32.67 $214,689 - $603,088	18,460 Added 70.15%	44,774 $804,000
Q3 2018 Oct 05, 2018	BUY	$29.37 - $49.48 $772,842 - $1.3 Million	26,314 New	26,314 $773,000
Q2 2018 Jul 17, 2018	SELL	$42.06 - $62.4 $672,202 - $997,276	-15,982 Closed	0 $0
Q1 2018 Apr 17, 2018	BUY	$50.12 - $67.72 $801,017 - $1.08 Million	15,982 New	15,982 $844,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.